News

The German Research Foundation (DFG) will fund single-cell scientist Simon Haas in its Heisenberg program. Therefore, the Berlin Institute of Health at Charité (BIH) is establishing a Heisenberg professorship in systems hematology. After five years, the BIH will make the professorship permanent.

A new computer program allows scientists to design synthetic DNA segments that indicate, in real time, the state of cells. Reported by the Gargiulo lab in “Nature Communications”, it will be used to screen for anti-cancer or viral infections drugs, or to improve gene and cell-based immunotherapies.

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

A tumor often arises when cancer genes multiply. In this process, additional genes act as hitchhikers, potentially creating previously unknown vulnerabilities that open the door to new therapeutic approaches. This finding is reported by a team led by ECRC-scientists Anton Henssen and Jan Dörr in "Cancer Discovery."

For his work on aggressive glioblastomas, Dr. Gaetano Gargiulo of the Max Delbrück Center received a 10,000 euro prize from the Berlin-Brandenburg Academy of Sciences and Humanities. Donated by the Monika Kutzner Stiftung, the prize honors outstanding achievements in cancer research.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers.

Swapping just a single amino acid can play a decisive role in transforming healthy B cells into cancer cells. An international team led by ECRC researcher Stephan Mathas describes in “Nature Communications” how a point mutation in the transcription factor IRF4 profoundly alters gene regulation.

Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, according to a new study by the Gerhardt and De Smet labs published in “EMBO Molecular Medicine.”

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.